A PHASE 3 OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE

Administered By

Pediatrics, Medical Genetics

Awarded By

Amicus Therapeutics Corporation

Contributors

Kishnani, Priya Sunil Principal Investigator

Start/End

April 13, 2020 - November 30, 2024